Alnylam Pharmaceuticals
ALNY
$339.41
+1.92%
Alnylam Pharmaceuticals is a biotechnology company and a pioneer in the development of RNA interference (RNAi) therapeutics, a platform for silencing disease-causing genes. The company is a clear market leader in the RNAi field, having successfully commercialized multiple drugs, including Onpattro, Amvuttra, Givlaari, and Oxlumo, primarily for rare genetic diseases. The current investor narrative is focused on the company's transition to sustainable profitability, driven by robust revenue growth from its commercial portfolio, while also debating the long-term growth trajectory and pipeline execution as it expands into new therapeutic areas like cardio-metabolic and neurological diseases.…
ALNY
Alnylam Pharmaceuticals
$339.41
Investment Opinion: Should I buy ALNY Today?
Rating & Thesis: Hold. ALNY presents a compelling but high-risk growth story at a crossroads, where its strong fundamental progress is counterbalanced by severe technical damage and a demanding valuation, making it prudent to await clearer signs of stabilization or a more attractive entry point. The mixed analyst actions—with recent Buy reiterations but one notable downgrade to Hold—reflect this uncertainty and lack of a clear near-term catalyst.
Supporting Evidence: The investment case is supported by 84.95% YoY revenue growth in Q4 2025, a transition to profitability with a net margin of 8.45% TTM, and robust free cash flow generation of $465.4 million. However, these are weighed against a prohibitive trailing P/E of 166.0x, a 30% six-month price decline indicating broken momentum, and quarterly revenue that dipped sequentially from Q3 to Q4, introducing volatility concerns.
Risks & Conditions: The two biggest risks are valuation compression from the extreme trailing P/E and a failure to sustain quarterly revenue growth momentum. This Hold rating would upgrade to a Buy if the stock demonstrates sustained technical support above $300 and reports next-quarter revenue that re-accelerates sequentially, confirming growth stability. It would downgrade to a Sell if the price breaks below the $300 psychological support level with volume, signaling a continuation toward the 52-week low, or if quarterly revenue growth decelerates sharply below 50% YoY. Relative to its history and the expectation of massive earnings growth, the stock is fairly valued on a forward basis but remains overvalued on a trailing basis, demanding perfect execution.
Sign up to view all
ALNY 12-Month Price Forecast
The AI assessment is neutral, balancing ALNY's undeniable fundamental strength—its profitable hyper-growth and cash generation—against severe technical headwinds and a valuation that prices in perfection. Confidence is medium because the outcome hinges heavily on the next few quarters' execution to validate the forward earnings expectations embedded in the 22.7x P/E. The key is whether revenue growth can stabilize sequentially and margins hold, providing the proof needed for multiple expansion. The stance would upgrade to bullish on a confirmed technical reversal above the $350 level coupled with sustained quarterly execution. It would turn bearish if the stock breaks below $300, signaling a failure of the current consolidation and a likely move toward the $220 support.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Alnylam Pharmaceuticals's 12-month outlook, with a consensus price target around $441.23 and implied upside of +30.0% versus the current price.
Average Target
$441.23
9 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
9
covering this stock
Price Range
$272 - $441
Analyst target range
Analyst coverage for ALNY appears limited in the provided dataset, with only recent rating actions from specific firms shown and no consolidated count, consensus recommendation, or average target price provided. The institutional ratings data shows a series of 'Buy' actions from firms like HC Wainwright, Chardan Capital, and Needham in early 2026, with one notable downgrade from Jefferies from 'Buy' to 'Hold' in mid-March 2026. The absence of a clear consensus target and the mixed signals from recent actions (mostly reiterations of Buy, one downgrade to Hold) suggests moderate but not overwhelming bullish sentiment, with the downgrade potentially reflecting concerns about the stock's recent sharp decline or near-term catalysts.
Bulls vs Bears: ALNY Investment Factors
The bull case for ALNY is powerfully supported by its fundamental transformation, evidenced by explosive 85% revenue growth and a recent pivot to profitability, strong cash flow, and an efficient capital structure. The bear case is equally compelling on a technical and sentiment basis, highlighted by a severe 30% six-month price decline, an extreme trailing valuation premium, and volatile quarterly results. Currently, the bearish technical momentum and valuation concerns appear to have the upper hand in the near term, as reflected in the stock's persistent downtrend. The single most important tension in the investment debate is whether the company's recent profitability and high growth rates are sustainable enough to justify its lofty trailing P/E of 166x and support a re-rating, or if quarterly volatility and execution risks will trigger further multiple compression, driving the price toward its 52-week low.
Bullish
- Explosive Revenue Growth & Profitability Turn: Q4 2025 revenue grew 84.95% YoY to $1.097 billion, demonstrating massive commercial traction. The company achieved consecutive profitable quarters in Q3 and Q4 2025, with Q4 net income of $186.4 million, marking a pivotal transition from a pre-profit biotech to a sustainably profitable enterprise.
- Strong Free Cash Flow & Efficient Capital Use: Trailing twelve-month free cash flow is a robust $465.4 million, indicating the business is generating significant cash from operations. This is complemented by an exceptional Return on Equity of 39.76%, signaling highly efficient use of shareholder capital.
- Attractive Forward Valuation vs. Trailing: The forward P/E of 22.7x is dramatically lower than the trailing P/E of 166.0x, reflecting market expectations for massive earnings growth. This forward multiple is more reasonable for a profitable growth biotech, especially given the 85% YoY revenue growth.
- Robust Balance Sheet Liquidity: The company maintains a strong current ratio of 2.76, providing ample liquidity to fund operations and R&D. While the debt-to-equity ratio of 1.62 indicates leverage, it is manageable given the strong cash generation and profitability.
Bearish
- Severe Price Downtrend & Momentum Loss: The stock is down 30.05% over six months and 19.13% over three months, indicating persistent and significant selling pressure. Despite a modest 0.52% one-month gain, the price remains deep in a downtrend, struggling to find sustained buying interest.
- Extremely High Trailing P/E Premium: A trailing P/E of 166.0x represents a massive premium to the biotechnology industry, embedding expectations for flawless future execution. This valuation leaves little room for error and makes the stock vulnerable to multiple compression if growth decelerates.
- Volatile Quarterly Revenue & Margins: Revenue declined from $1.249 billion in Q3 to $1.097 billion in Q4 2025, showing quarter-to-quarter volatility that may concern investors. Gross margins have fluctuated from 88.04% in Q1 to 75.6% in Q4, indicating potential product mix or pricing instability.
- Mixed Analyst Sentiment & Recent Downgrade: While several firms reiterated Buy ratings in early 2026, Jefferies downgraded ALNY from Buy to Hold in mid-March 2026. The lack of a clear consensus target price and this downgrade suggest growing caution among analysts regarding near-term catalysts or valuation.
ALNY Technical Analysis
The stock is in a pronounced downtrend, having declined 30.05% over the past six months and 19.13% over the last three months. As of the latest close at $322.11, the price is trading at approximately 65% of its 52-week range ($220.54 to $495.55), positioning it significantly off its highs and suggesting a potential value opportunity, though the persistent downward momentum indicates significant selling pressure. Recent short-term momentum shows a slight divergence, with a modest 0.52% gain over the past month, which could signal a potential stabilization or a pause in the downtrend, but this nascent recovery is fragile against the backdrop of a 19.13% three-month loss. Key technical support is clearly defined at the 52-week low of $220.54, while resistance sits near the 52-week high of $495.55; a sustained break below support would signal a continuation of the bearish trend, whereas reclaiming the $400 level would be an initial step toward recovery. The stock's beta of 0.383 indicates it has been significantly less volatile than the broader market over the measured period, which is unusual for a biotech stock and may reflect a shift in its risk profile as it matures, though the recent price action suggests idiosyncratic company-specific risks are dominating.
Beta
0.38
0.38x market volatility
Max Drawdown
-37.6%
Largest decline past year
52-Week Range
$226-$496
Price range past year
Annual Return
+41.4%
Cumulative gain past year
| Period | ALNY Return | S&P 500 |
|---|---|---|
| 1m | +8.3% | +4.9% |
| 3m | -7.5% | +0.6% |
| 6m | -29.4% | +5.1% |
| 1y | +41.4% | +28.8% |
| ytd | -15.2% | +1.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALNY Fundamental Analysis
Revenue growth is exceptionally strong but volatile on a quarterly basis; the most recent Q4 2025 revenue was $1.097 billion, representing a massive 84.95% year-over-year growth, though this followed a Q3 revenue of $1.249 billion, indicating some quarter-to-quarter fluctuation. The company achieved profitability in the last two reported quarters, with Q4 net income of $186.4 million and a gross margin of 75.6%, demonstrating a significant improvement from losses in the first half of 2025 (Q2 net loss of -$66.3 million) and highlighting a successful pivot toward sustainable operations. Profitability metrics are strengthening, with the trailing twelve-month net margin at 8.45% and operating margin at 13.51%, though quarterly gross margins have ranged from a high of 88.04% in Q1 2025 to 75.6% in Q4, suggesting some product mix variability. The balance sheet shows a debt-to-equity ratio of 1.62, indicating a leveraged but manageable capital structure, supported by strong liquidity with a current ratio of 2.76 and robust cash generation evidenced by free cash flow of $465.4 million over the trailing twelve months and an impressive return on equity of 39.76%, signaling efficient use of shareholder capital.
Quarterly Revenue
$1.1B
2025-12
Revenue YoY Growth
+0.84%
YoY Comparison
Gross Margin
+0.75%
Latest Quarter
Free Cash Flow
$465383000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALNY Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E is extremely high at 166.0x, while the forward P/E is a much lower 22.7x; this massive gap implies the market is pricing in exceptionally high future earnings growth, expecting significant profit expansion from the recent baseline. Compared to typical biotechnology industry averages, a trailing P/E of 166x represents a substantial premium, which is likely justified by Alnylam's unique leadership in the commercialized RNAi space and its rapid transition to profitability, though it also embeds high expectations for flawless execution. Historically, the stock's own valuation has been volatile; the current trailing P/E of 166x is below the peak of 256x seen in Q3 2025 but remains elevated compared to its deeply negative P/E ratios throughout much of 2024, indicating the market is now valuing it as a profitable growth company rather than a pre-profit biotech, but still at a level demanding continued strong performance.
PE
166.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -456x~71x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
92.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Alnylam's primary financial risk stems from its extreme valuation premium, with a trailing P/E of 166x demanding uninterrupted hyper-growth. Quarterly revenue volatility is a concern, as Q4 2025 sales of $1.097B represented a sequential decline from Q3's $1.249B, raising questions about the stability of its commercial ramp. While the debt-to-equity ratio of 1.62 is manageable, it introduces financial leverage risk if profitability proves less durable than expected, especially given the fluctuation in quarterly gross margins from 88% to 76%.
Market & Competitive Risks: The stock faces significant valuation compression risk; trading at a forward P/E of 22.7x still implies high growth expectations, and any disappointment could lead to a sharp de-rating similar to the 30% decline already experienced. Competitive risks are inherent in biotechnology, where next-generation platforms or therapies could challenge Alnylam's RNAi leadership. The stock's low beta of 0.383 is deceptive; recent price action shows it is dominated by idiosyncratic, company-specific risks rather than market movements, making it susceptible to negative clinical or commercial news.
Worst-Case Scenario: The worst-case scenario involves a combination of slowing revenue growth, a pipeline setback in a key clinical program (e.g., in cardio-metabolic or neurology), and a broader biotech sector downturn. This could trigger a cascade of analyst downgrades and a loss of investor confidence in the sustainability of its profitability. The realistic downside would be a retest of the 52-week low of $220.54, representing a loss of approximately 31.5% from the current price of $322.11. A drawdown of this magnitude is plausible, given the stock's historical max drawdown of -37.57% within the provided data period.
FAQ
The key risks are: 1) Valuation Risk: The extreme trailing P/E of 166x makes the stock vulnerable to multiple compression if growth expectations are not met. 2) Execution Risk: Quarterly revenue has shown volatility (Q4 $1.097B down from Q3 $1.249B), and margins fluctuate, raising concerns about sustainable growth. 3) Pipeline & Competitive Risk: Future growth depends on successful clinical trials in new therapeutic areas and maintaining leadership against emerging RNA-based therapies. 4) Technical Risk: The stock is in a pronounced downtrend, down 30% over six months, indicating persistent selling pressure that could continue.
The 12-month forecast for ALNY is bifurcated with a base case target range of $320-$380 (50% probability), a bull case of $450-$495 (30% probability), and a bear case of $220-$280 (20% probability). The base case, which is most likely, assumes the company meets forward EPS estimates near $19.26, growth stabilizes, and the stock's valuation multiple holds steady. The forecast hinges critically on the company's ability to demonstrate consistent quarterly revenue growth and profitability in the coming reports, which will determine whether the stock remains range-bound or breaks toward one of the more extreme scenarios.
ALNY's valuation presents a dual picture: it is severely overvalued based on trailing earnings with a P/E of 166x, but appears more reasonably valued on a forward basis with a P/E of 22.7x, assuming massive profit growth materializes. Compared to typical biotech stocks, the trailing multiple is a substantial premium, justified only by its unique market position and recent profitability turn. The forward multiple implies the market expects earnings to grow nearly 7.3x from the trailing baseline. Therefore, the stock is fairly valued only if you have high conviction in the forward estimates; otherwise, it remains expensive relative to its current earnings.
ALNY is a high-risk, high-reward stock that may be a good buy for aggressive growth investors who believe in the long-term dominance of its RNAi platform and can tolerate significant volatility. The stock offers potential upside if it re-rates toward its 52-week high of $495, but carries a 31.5% downside risk to its 52-week low of $220. Given its current Hold rating, it is not an unequivocal 'good buy' for all investors; it is more suitable for those already holding or those waiting for a more compelling technical entry point, such as a confirmed breakout above $350 or a deeper pullback toward stronger support levels.
ALNY is primarily suitable for long-term investment, given its status as a growth-stage biotech where the full value of its platform and pipeline will be realized over years. The stock's low beta of 0.383 and lack of dividend support a buy-and-hold strategy for investors believing in the RNAi thesis. However, its recent high volatility and technical downtrend make it a challenging short-term trade. A minimum holding period of 3-5 years is suggested to weather clinical trial cycles and commercial ramp-up phases, allowing the fundamental story to play out beyond near-term quarterly noise.